Illumina Inc.'s plan to take over Solexa Inc. in a $600 million stock swap recalls the buyout of CyVera Corp. early last year, which provided Illumina an entry into the diagnostics field. (BioWorld Today)
Genentech Inc.'s planned takeover of Tanox Inc. for $20 per share, or $919 million - about $650 million net of cash - would end the royalty payout to Tanox on U.S. sales of the asthma drug Xolair from Genentech, which would also get the royalties Novartis AG has been providing Tanox as part of the companies' three-way deal. (BioWorld Today)
Pipex Therapeutics Inc. merged with the shell company Sheffield Pharmaceuticals Inc., disclosing at the same time positive data from the pivotal Phase III trial with its lead candidate Coprexa for Wilson's disease. (BioWorld Today)
Wyeth juiced Inovio Biomedical Corp.'s bottom line with a potential $64.5 million, nonexclusive licensing deal that gives the pharma giant rights to use MedPulser electroporation delivery technology in DNA vaccines. (BioWorld Today)
The latest snag for VaxGen's anthrax vaccine sent shares down by more than half after the company said the FDA put rPA102 on clinical hold, delaying the second Phase II trial. (BioWorld Today)
On the heels of a 1-for-10 reverse stock split that could help get the firm listed for trading in the U.S., broad-pipelined MediciNova Inc. - which went public in Japan early last year - filed a shelf registration with the SEC for the sale of up to $100 million in shares. (BioWorld Today)
